Company
Ipsen
Ipsen has 32 drugs tracked on RxWires: 6 post-market, 5 in Phase 3, 1 in Phase 2/3, 5 in Phase 2, 6 in Phase 1/2, 9 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| PEG 4000 (Forlax ®) | Post-Market | Constipation |
| AbobotulinumtoxinA | Post-Market | Compartment Syndrome of Leg |
| Botulinum toxin type A | Post-Market | Muscle Spasticity |
| Smecta | Post-Market | Acute Diarrhoea |
| Abobotulinum toxin A | Post-Market | Tremor, Limb |
| Lanreotide (Autogel formulation) | Post-Market | Acromegaly |
| Telotristat Ethyl | Phase 3 | Small Intestinal NET |
| Elafibranor 80mg | Phase 3 | Primary Biliary Cirrhosis |
| Corabotase | Phase 3 | Moderate to Severe Glabellar Lines |
| Triptorelin Pamoate 11.25mg | Phase 3 | Prostate Cancer |
| Lanreotide Autogel® | Phase 3 | Acromegaly |
| mecasermin | Phase 2/3 | Growth Hormone Insensitivity Syndrome |
| BIM23B065 | Phase 2 | Acromegaly |
| Cabozantinib | Phase 2 | Locally Advanced or Metastatic Renal Cell Carcinoma |
| nal-IRI | Phase 2 | Pancreatic Cancer |
| BIM 23A760 | Phase 2 | Acromegaly |
| Pembrolizumab | Phase 2 | Triple Negative Breast Cancer |
| Satoreotide tetraxetan | Phase 1/2 | Neuroendocrine Tumors |
| Tazemetostat | Phase 1/2 | Relapsed Hematologic Malignancy |
| IPN60300 | Phase 1/2 | Locally Advanced Solid Tumor |
| IPN01194 | Phase 1/2 | Melanoma |
| IPN01195 | Phase 1/2 | Advanced Solid Tumor |
| Onivyde | Phase 1/2 | Recurrent Solid Tumor |
| BN80927 | Phase 1 | Malignant Solid Tumour |
| nanoliposomal irinotecan | Phase 1 | High Grade Glioma |
| Tovorafenib | Phase 1 | Low-grade Glioma |
| 111In-IPN01087 Low dose | Phase 1 | Pancreatic Ductal Adenocarcinoma |
| BN83495 (Cohort 1) | Phase 1 | Prostate Cancer |
| telotristat etiprate | Phase 1 | Hepatic Impairment |
| Tazemetostat and [14C] Tazemetostat | Phase 1 | Diffuse Large B Cell Lymphoma |
| Ferumoxytol | Phase 1 | Solid Tumors |
| Irosustat (BN83495) | Phase 1 | Breast Cancer |
Latest
Follow Ipsen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.